Inositol
Trials 36 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 14 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01574261 Comparator | Mar → Aug 2012 | polycystic ovary syndrome | Catholic University of the Sacred Heart | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06170463 Comparator | Aug 2022 → Mar 2023 | polycystic ovary syndrome | Zagazig University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03153436 Comparator | Aug 2016 → Apr 2017 | — | Sohag University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04867252 Comparator | May → Aug 2021 | polycystic ovary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 2 | NCT02633462 Comparator | May 2015 → Oct 2016 | periodontitis, polycystic ovary syndrome | Postgraduate Institute of Dental Sciences Rohtak | Unknown | No outcome recorded |
| Phase 2 | NCT01875445 Comparator | May 2013 → May 2016 | trichotillomania | University of Chicago | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07585396 Comparator | May 2025 → May 2026 | infertility disorder, polycystic ovary syndrome | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07630779 Background | Mar → Sep 2026 expected | polycystic ovary syndrome | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03283813 Comparator | Feb 2018 → Dec 2023 | disorder of zinc metabolism, obesity disorder | Azienda Ospedaliero Universitaria Maggiore della Carita | Completed | No outcome recorded |
| Phase 4 | NCT01396486 Comparator | Feb 2012 → Apr 2019 | bipolar disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07058675 Comparator | Nov 2024 → May 2025 | polycystic ovary syndrome | Benha University | Completed | No outcome recorded |
| — | NCT01555190 Comparator | Jan 2012 → Dec 2013 | hypertrichosis, menstrual disorder, polycystic ovary syndrome | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT01791647 Comparator | Jun 2011 → Dec 2012 | polycystic ovary syndrome | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT02397291 Comparator | Jan 2001 → Dec 2016 | fetal growth restriction | University of Colorado, Denver | Terminated | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inositol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01030575 ↗ |
| Known as | Cyclohexanehexol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222251 ↗ |
| Known as | I-inositol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222251 ↗ |
| Known as | Inositol, myo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222251 ↗ |
| Known as | Meso-inositol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222251 ↗ |
| Known as | MYO | “myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratiotwice daily” NCT07058675 ↗ |
| Known as | Myo-inositol | “This group is given myoinositol+d-chiro inositol+folic acid once a day (inofolic combi, ITF company, Italy) (myoinositol 550 miligram+ d-chiroinositol 13,8 miligram+folic acid...” NCT05951309 ↗38“Myo-inositol (MI) is one of the most important of the 9 inositol stereoisomers, and this molecule has been studied many times in the literature in recent years.” NCT05943158 ↗ “Participants allocated to this arm will receive myo-inositol 2 g orally twice daily for a duration of 3 months prior to ovulation induction.” NCT07635082 ↗ “The promising role of two of its isomers namely Myo-inositol (MI) and D-chiro-inositol (DCI) in the treatment of PCOS has been documented.” NCT05767515 ↗ “The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.” NCT07459595 ↗ “Myo-Inositol is a carbocyclic sugar, belongs to Inositol group and is an important component of structural lipids.” NCT04867252 ↗ “Myo-inositol (MI) protects against MAFLD through reduction of hepatic accumulation of triglycerides.” NCT06170463 ↗ “60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.” NCT00349726 ↗ “Levocarnitine 330 mg and Myoinositol 750 mg twice daily for 3 months” NCT07266259 ↗ |
| Known as | NSC-25142 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222251 ↗ |
| Known as | NSC-404118 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222251 ↗ |
| Known as | NSC-55551 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222251 ↗ |
| Known as | NSC-8101 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1222251 ↗ |
| Modality | Other / unclassified | “Inositol, a dietary supplement” NCT03864068 ↗ |
| Route | Intravenous | “given intravenously over 20 minutes.” NCT00349726 ↗ |